To understand the prevalence of LAMA2 mutations, we examined data from other studies, and found that approximately 6% (5/88) of the samples in the Asia Cancer Research Group study [4], and approximately 5% (5/104) of the samples in the Riken liver cancer cohort from the International Cancer Genome Consortium also had LAMA2 mutations. This evidence concerns the gene LAMA2 and cancer.